Hydroxyprogesterone Caproate

The FDA allowed compounding pharmacies to compete with Makena, a high-priced drug, to address public outcry, setting a precedent that could undermine broader public health obligations. The FDA's stance on compounding GLP-1 drugs for weight loss, initially due to shortages, now risks setting a similar precedent. Pharmacy compounding, essential for specific patient needs, was not intended to compete with branded drugs, a role for generic drugs. The FDA's selective enforcement on drug pricing could face more pressure to loosen oversight, impacting critical policies.

Tara Skopelitis and Sholto David flagged papers misnaming a medication for pregnant women, leading to one retraction and three corrections. Skopelitis, who received the wrong progesterone for her daughter, identified 69 misnamed papers. The confusion stems from literature treating 17P and intramuscular progesterone as interchangeable, despite the latter not being tested for safety in preventing preterm labor.